Moderna’s anti-Covid vaccine has also shown efficacy in adolescents: no cases of Covid-19 have been observed after the two doses, consistent with a vaccine efficacy of 93% two weeks after the first dose and 100% after the second.
This was revealed by the data announced today by Moderna relating to the TeenCOVE study on adolescents. “We are motivated by the fact that mRNA has been highly effective in preventing Covid-19 in adolescents – said Stéphane Bancel, CEO of Moderna -. We will send these results to the FDA and other regulatory bodies in early June, asking for authorization. “.
Anti-Covid vaccines: the rules for children and adolescents
by Donatella Zorzetto
The primary objective of immunogenicity of no less than that of the adult comparison group of the phase 3 study was achieved, explains Moderna in a note. Furthermore, “no cases of Covid-19 were observed after the two doses of vaccine” , “consistent with a vaccine efficacy of 100%”. And “using the Center for Disease Control and Prevention (CDC) case definition, 93% vaccine efficacy was observed after the first dose. No significant safety concerns were reported.”
Covid, a new App will monitor the safety of vaccines
The TeenCOVE study enrolled more than 3,700 participants between the ages of 12 and 18 in the United States.
Covid vaccines for teens, how they work and which ones could be approved
by Valeria Pini
“We are motivated by the fact that mRNA-1273 has been highly effective in preventing Covid-19 in adolescents. It is particularly exciting to see that Moderna Covid-19 vaccine can prevent Sars-Cov-2 infection,” he said. Stephane Bancel, CEO of Moderna -. We will send these results to the US FDA and other global regulators in early June, requesting their authorization. We continue to be committed to our work to help end the Covid-19 pandemic. ”
Covid vaccine side effects: “Why does it hurt me and others don’t?”
by Donatella Zorzetto
A favorable opinion from the EMA on the use of the Pfizer vaccine for adolescents is expected on May 28th.
.